Results of a Phase I clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a lower risk of relapse and lower rates of graft-versus-host disease when they receive the targeted therapy VIC-1911 along with the standard-of-care regimen that includes post-transplant cyclophosphamide and sirolimus.
Continue Reading this article here
